Clarivate Completes Sale of Life Sciences & Healthcare Segment, Advances Strategic Transformation
PR Newswire•06/10/2026•16:15 ET
0
Key Highlights
- ➤$600 million Life Sciences & Healthcare sale to Altaris completed
- ➤Proceeds intended to reduce debt and strengthen Clarivate’s balance sheet
- ➤Clarivate now focused on Academia & Government and Intellectual Property segments
- ➤Third-quarter 2026 results due November 3; full-year guidance will reflect divestiture
Expert Statements
Matti Shem Tov, Chief Executive Officer, Clarivate
“This is an important milestone in Clarivate's transformation journey. The successful completion of this transaction further advances our Value Creation Plan by sharpening our focus, simplifying our portfolio, and strengthening our financial profile. We are now positioned as a more focused company centered on two market-leading segments with attractive recurring revenue characteristics, deep customer relationships, and significant opportunities to leverage AI-driven innovation.”
Matti Shem Tov, Chief Executive Officer, Clarivate
“I want to thank our Life Sciences & Healthcare colleagues for their many contributions to Clarivate and wish them continued success as part of Altaris”
Matti Shem Tov, Chief Executive Officer, Clarivate
“We also thank our customers for their continued trust and partnership throughout this process.”
Michael Easton, Chief Financial Officer, Clarivate
“The completion of this transaction marks another meaningful step in executing our strategy. Our streamlined business model and stronger balance sheet position us well to invest in innovation, support our customers, and drive sustainable growth and shareholder value.”
Clarivate Completes Sale of Life Sciences & Healthcare Segment, Advances Strategic Transformation PR Newswire
Transaction sharpens strategic focus on leading Academia & Government and Intellectual Property segments
Get started
Create a free account to read the full story.